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Abstract
Background and Study Objectives—Transfusions are the primary therapy for thalassemia 
but have significant cumulative risks. In 2004, the Centers for Disease Control and Prevention 
(CDC) established a national blood safety monitoring program for thalassemia. The purpose of 
this report is to summarize the patient population as well as previous non-immune and immune 
transfusion complications at the time of enrollment into the program. A focus on factors associated 
with allo- and auto-immunization in chronically transfused patients and a description of blood 
product preparation and transfusion practices at the participating institutions are included.
Study Design and Methods—The CDC Thalassemia Blood Safety Network is a consortium 
of thalassemia centers, longitudinally following patients to determine transfusion-related 
complications. Enrollment occurred from 2004 through 2012 and annual data collection is 
ongoing. Demographic data, transfusion history, and previous transfusion and non-transfusion 
complications were summarized for patients enrolled between 2004 and 2011. Logistic analyses of 
factors associated with allo- and auto-immunization were developed. Summary statistics of 
infections reported at the time of enrollment were also calculated.
Results—The race/ethnicity of the 407 thalassemia patients enrolled in the Network was 
predominantly Asian or Caucasian and 27% were immigrants. The average age was 22.3 years ± 
13.2 and patients received an average total number of 149 ± 103.4 units of red blood cells. Iron-
induced multi-organ dysfunction was common despite chelation. At study entry, 86 patients had 
previously been exposed to possible transfusion-associated pathogens, including Hepatitis-C (61), 
Hepatitis B (20), Hepatitis A (3), Parvovirus (9), HIV (4), malaria (1), staphylococcus aureus (1) 
and babesia (1). As 27% of the population was born outside of the United States (India, Pakistan, 
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Thailand, China, Vietnam and Iran accounting for 57%), the source of infection cannot be 
unequivocally tied to transfusion. In total, 24% of transfused patients were reported to have 
possible transfusion-associated pathogens. Transfusion reactions occurred in 48% of patients, 
including allergic, febrile, and hemolytic; 19% of transfused patients were alloimmunized (defined 
as a having an antibody to a foreign red blood cell antigen). The most common antigens were E, 
Kell and C. One hemolytic reaction to an anti-Mia antibody was noted. Years of transfusion was 
the strongest predictor of alloimmunization. However, initiating transfusions in infancy may 
induce immune tolerance. Autoantibodies occurred in 6.5% and were predicted by previous 
alloimmunization (p < .0001). Local institutional transfusion policies, rather than patient 
characteristics, were the major determinants in the preparation of red-blood cells for transfusion.
Conclusion—Hemosiderosis and immunologic and non-immunologic transfusion reactions are 
major problems in thalassemia patients. Infections continue to be a problem in thalassemia and 
new pathogens have been noted. National transfusion guidelines for red cell phenotyping and 
preparation are needed in thalassemia to decrease transfusion-related morbidity.
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INTRODUCTION
Worldwide, there are over 60,000 births annually of serious forms of thalassemia.1,2 The 
World Health Organization considers thalassemia to be a major health burden.1,2 
Transfusions are the primary therapy for thalassemia but have significant risks including 
hemosiderosis, transfusion reactions, alloimmunization, and infections. In 1998, Congress 
and the Centers for Disease Control and Prevention (CDC) established a blood safety 
monitoring surveillance system called the Universal Data Collection (UDC) Project. In 
2004, this program was expanded to include thalassemia. The goals of the program are to 
monitor blood safety and to develop and test strategies for the prevention and management 
of complications in patients with thalassemia.
The distributions of the phenotype and genotype of North American thalassemia patients 
today, as well as their transfusion management, are dramatically different from those in the 
past decades.3 The majority of patients, previously of Mediterranean descent, are now 
largely of Asian and Middle Eastern origin.3 The diverse thalassemia phenotypes found in 
this population results in different transfusion exposure than the Mediterranean population. 
There is limited data on the transfusion complications in this population including 
alloimmunization rates. Pilot data suggests this diverse population in North America may be 
at greater risk for alloimmunization.3–13 Knowledge of other transfusion complications such 
as anaphylaxis and hemolytic reactions is also incomplete because these events are rarely 
compiled and reported. Importantly, the thalassemia population, which has the highest 
transfusion exposure of chronic diseases, provides the opportunity to study emerging 
transfusion-associated infections.
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The purpose of this report is to summarize the patient population of the CDC Thalassemia 
Blood Safety Network as well as previous non-immune and immune complications at the 
time of enrollment into the program. A focus on factors associated with allo- and auto-
immunization in chronically transfused patients and a description of blood product 
preparation and transfusion practices at the participating institutions are included.
MATERIALS AND METHODS
The CDC Thalassemia Blood Safety Network (Network) is a consortium of thalassemia 
centers in the United States that has a longitudinal cohort study of patients to determine risk 
factors for transfusion-related complications. This report describes the population at the time 
of their enrollment between 2004 and 2011. Individuals from thalassemia centers located in 
Boston, MA; Chicago, IL; Philadelphia, PA; New York, NY; Oakland, CA; Los Angeles, 
CA; and Atlanta, GA participated.
Demographic, physical examination, and laboratory data were collected at enrollment and 
entered into a central database at the CDC. Demographic data collected included clinical 
diagnosis, gender, race, ethnicity, genotype and phenotype. Historical data included 
information regarding immunizations, infection exposures, surgical procedures, organ 
dysfunction, age of transfusion initiation, chelation therapy, type of red cell product, 
transfusion reactions, and antigen matching. Data were collected from chart review, patient 
interviews, blood banking records, and laboratory testing. Organ dysfunction was defined as 
a history of requiring medical treatment for heart disease, diabetes (type 1 or 2), 
hypoparathyroidism, hypothyroidism, growth hormone deficiency or gonadal failure.
Infection
Information on previous exposure to infectious pathogens was collected on enrollment 
intake forms. In addition, specimens were mailed to the CDC annually for pathogen 
screening. The protocol and standard assays are provided in Appendix 2. Institutional 
Review Board approval of the protocol and consent forms was obtained at all participating 
institutions and consent forms were signed by each patient prior to enrollment.
Transfusion Complications
Adverse transfusion reactions were reported according to a Manual of Operations based on 
National Healthcare Safety Network Hemovigilance Module published transfusion 
complication definitions including: hemolytic transfusion reactions (acute, delayed), febrile 
non-hemolytic, allergic, transfusion-associated circulatory overload, transfusion-related 
acute lung injury, post-transfusion purpura, transfusion-associated GVHD, transfusion-
transmitted infection, hypotensive reactions, and transfusion–associated dyspnea.14,15 
Alloimmunization was defined as a having an antibody to a foreign red blood cell antigen 
while autoimmunization was defined as the presence of an antibody to an antigen on the 
patients’ own red cells.
Transfusion Protocol Guidelines and Institutional Practices—Data were collected 
regarding institutional practices related to transfusion. A prospective questionnaire was sent 
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to the participating institutions and their principal investigator regarding their institution’s 
preparation methods of red cell products and transfusion practices. Preparation methods of 
red cells was classified as leukoreduced (by filtration methods), washed, and/or irradiated. 
Data regarding screening for alloantibodies and autoantibodies at each thalassemia center 
was obtained. Antigen matching was determined as one of three categories: ABO/D; 
ABO/D, C, E, Kell; and “extended.”
Statistical Methods—Patients were characterized as “chronically transfused” if they had 
a history of chronic transfusions and received eight or more transfusions within a 12 month 
period, “intermittently transfused” if they had not been chronically transfused but had 
received one to seven transfusions within a 12 month period, or “never transfused” at the 
date of study entry. Patients were classified as β-thalassemia Major (TM), β-thalassemia 
Intermedia (TI), Hemoglobin (Hb) E-β-thalassemia (E-thal) or α-thalassemia (α-thal) 
syndrome (including HbH disease and HbH/Constant Spring) based on their diagnosis, 
clinical course, and genotype. Demographic variables such as age, gender, and race were 
summarized for the total population and for each transfusion group. For chronically 
transfused patients, the years of transfusion exposure was calculated by subtracting the age 
at which the patient began transfusion from their age at enrollment. Continuous variables 
such as current age, age at start of transfusion therapy, and number of transfusions in the 
year prior to enrollment were compared between the transfusion groups utilizing ANOVA or 
Student's t-tests. Discrete variables, such as the prevalence of alloimmunization, were 
compared across groups utilizing chi-square or Fisher’s exact tests. Logistic regression 
models were used to identify independent predictors of allo- and auto-immunization status 
in chronically transfused patients. All analyses were performed at the data coordinating 




Of the 407 thalassemia patients enrolled in the CDC transfusion surveillance study between 
2004 and 2011, 284 (70%) patients were diagnosed as TM, 58 (14%) α-thal syndromes, 37 
(9%) TI, and 28 (7%) E-thal. Fifty-five percent of participants were female. There were two 
major racial groups: Asian (207) and White (175) which accounted for 94% of the 
population. An additional 4% were classified as Black (see Table 1). Seventy-three percent 
of the population was born in the United States, and 27% outside the United States (India, 
Pakistan, Thailand, China, Vietnam and Iran accounting for 57%). Of the 110 patients born 
outside of the US, 104 were transfused and the majority started transfusion therapy before 
their first visit to a US Thalassemia Treatment Center (TTC), although data about the 
location or other details of these transfusions is not available.
Eighty percent (327) of the patients had been chronically transfused, 9% (38) had only been 
intermittently transfused, and 10% (42) were never transfused (Table 1). Diagnostic 
categories of the patients who had been chronically transfused included: TM (82%), TI 
(6%), E-thal (6%), and α-thal syndromes (6%). Forty-nine percent of the chronically 
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transfused patients were White and 48% Asian. At study entry, the median age of the 
chronically transfused patients was 31.3 years, range <1 to 58. The median age of 
transfusion initiation was 1 year with a mean age of 4.5 ± 8.2 years. The mean estimated 
years of transfusion exposure was 18.5 ± 12.3. The average number of transfusions in this 
group during the year prior to enrollment was 15.6 ± 5.8.
Among the 38 intermittently transfused patients, there were 15 α-thal syndromes, 11 TM, 8 
TI, and 4 E-thal patients. The median age was 17.3 years with a range of 1 to 61. The 
proportion of Asians in the intermittently transfused group was higher than in the 
chronically transfused group: 68% vs. 48% (p = 0.02). Also, the percentage of females was 
higher: 76% compared to 53% (p =0.007). Most patients with β0 thalassemia major were 
chronically transfused; 4%, however, were included in the intermittently transfused 
population receiving less than 8 annual transfusions in some years. As transfusion was 
intermittent in this group, an estimate of the years of transfusion exposure was not possible.
The diagnostic categories in the patients who had never been transfused were: 23 patients 
with α-thal syndromes, 9 patients with TI, 6 TM, and 4 E-thal. Untransfused patients were 
younger with a median age of 7 years (range 1 to 53). Thalassemia major patients in the 
non-transfused category were young infants under the age of one year who had not yet 
begun chronic transfusion at study enrollment.
General Complications
Hemosiderosis occurred in all groups. As expected, the average measurement of ferritin was 
significantly higher in the chronically transfused patients (median=1375.85 µg/L) compared 
to the other two groups (intermittent: 356 µ/L; non-transfused: 80.5 µ/L; p < 0.0001). 
Seventy-eight percent of all patients had received chelation therapy. In the total population, 
a history of organ dysfunction requiring medical treatment was common and included: 
cardiac disease (13%), gonadal failure (17%), growth hormone deficiency (8%), 
hypothyroidism (8%), hypoparathyroidism (1%), diabetes (10%), cirrhosis (2%), and 
thrombotic events (7%). Sixteen and a half percent had more than one organ system 
involved. Thrombotic events were often serious, and included 6 cases of pulmonary 
embolism, 5 superior vena cava syndromes, 4 deep vein thromboses, 3 cardiac thromboses, 
2 portal vein thromboses, and 2 patients with renal thrombosis. Of the 26 chronic transfusion 
patients with thrombosis, 25 had a splenectomy and 21 had concomitant central venous 
access. Overall, 31 patients were on chronic anticoagulant therapy. Most complications 
occurred in the chronically transfused population; however, cardiac, gonadal, thrombotic, 
and other complications were noted in 16% of the intermittently transfused.
Surgical procedures were common in this population. Splenectomy was reported in 45% of 
patients, and was more prevalent in the transfused patients: 52% in chronically transfused, 
29% in intermittently transfused, and 7% non-transfused (p < 0.0001). The mean age at the 
time of splenectomy was 10 years ±6.3. The majority of splenectomies occurred before 15 
years of age, with 20% occurring before age 5. Asians were less likely than Whites to have 
undergone splenectomy (32% vs. 65%, p < 0.0001). However, Asians were younger (17.9 ± 
9.6) compared to Caucasians (27.5 ± 14.7). Other procedures included central venous access 
devices in 27% and cholecystectomy in 14% of patients.
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Infections—At study entry, 86 patients’ intake forms revealed previous exposure to 
transfusion-associated infectious diseases, including Hepatitis C (61), Hepatitis B (20), 
Hepatitis A (3), Parvovirus (9), HIV (4), malaria (1), staphylococcus aureus (1) and babesia 
(1). In total, 24% of transfused patients had laboratory evidence of previous exposure to one 
or more infectious diseases.
Transfusion Complications—A history of transfusion reactions was reported in 48% of 
transfused patients. Chronically transfused patients were more likely to have had a reaction 
than intermittently transfused patients (50% vs. 22%, p = 0.002). Transfusion reactions 
occurred in 55% of males compared to 42% of females (p = 0.02) but were not related to 
race or splenectomy status.
Fifty-two percent of patients with transfusion reactions reported having only an allergic 
reaction, 16% experienced only febrile reactions, and 27% had multiple transfusion 
reactions of varied types. Most allergic reactions were mild to moderate in severity; however 
there were two anaphylactic reactions, one transfusion-associated hypotensive event and one 
episode of transfusion-associated dyspnea. There were 17 reported hemolytic transfusion 
reactions. Source documents were able to confirm nine of these were hemolytic 
immunologic transfusion reactions. The other cases occurred with allergic and febrile 
reactions but did not provide immunologic testing or laboratory evidence of hemolysis. 
Other complications included transfusion-associated tachycardia, acute vertigo, and transient 
vomiting. There were no episodes of transfusion-related acute lung injury.
Alloantibodies: Overall, 19% (68/365) of all transfused patients had alloantibodies. 
Twenty-three percent of chronically-transfused patients were alloimmunized, compared to 
13% of the intermittently-transfused (p=.30) Forty-seven percent of alloimmunized patients 
had multiple antibodies: Anti-E, anti-K or anti-C were identified in 70% of these patients 
(Table 2). One TM patient of Chinese ancestry developed anti-Mia antibody. The hemolytic 
transfusion reactions that occurred were caused by anti-E, anti-Jkb, anti-c, anti-Jka, anti-S, 
anti-Kell, anti-f, and two cases of warm autoantibodies.15 Current age, race, and 
splenectomy were also associated with alloimmunization. The average age of patients with 
alloantibodies was 29.4 years (± 13.3, n=68), and in those without, 20 years (± 12.5, n=261). 
Caucasians were more often alloimmunized than Asians (29% vs. 13%, p < 0.0001). 
Alloimmunization was found in 31% of splenectomized patients vs. 11% of non-
splenectomized patients (p < 0.0001).
Predictors of Alloimmunization in chronically transfused: In the chronically transfused 
patients only, the age at which patients began transfusion was significantly associated with 
the alloimmunization and reflected transfusion exposure. However, in those who began 
transfusion before one year of age, the proportion of allo-immunized patients was lower 
despite greater transfusion burden: 11% vs. 18 to 31% in the older age groups (Table 3). The 
average years of transfusion exposure in alloimmunized patients was higher (25.9 ± 13.1, 
n=64) vs. the non-alloimmunized (16.4 ± 11.1, n=226; p < .0001). The average number of 
transfusions received the year prior to enrollment in alloimmunized patients was 18 ± 6.6 
(n=64) vs. 15.2 ± 5.2 (n=235) in patients without alloantibodies (p = 0.003). In a stepwise 
multivariate logistic regression of alloantibody formation in chronically transfused patients 
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-- which included age at study enrollment (left as a continuous variable), years of 
transfusion, race (Asian vs. White), and splenectomy status -- only years of transfusion 
remained a significant independent predictor of alloimmunization (table 4).
Predictors of Autoimmunization: Autoantibodies occurred in 6.5% of patients; chronically 
transfused and intermittently transfused patients had a similar risk (6.4% vs. 6.9%). Patients 
with autoantibodies were significantly older than those without (27 years ± 13 vs. 21 ± 13, p 
= 0.0395). In chronically transfused patients, the risk of autoantibody formation was 10% in 
splenectomized patients compared to 3% in non-splenectomized patients (p = 0.02). Years 
of transfusion exposure, race, and gender were not associated with the rate of 
autoimmunization. Eighty-four percent of patients with autoantibodies were alloimmunized, 
in contrast to only 17% of those without autoantibodies (p < 0.0001). A stepwise 
multivariate logistic regression analysis of autoantibody formation in chronically transfused 
patients included age at study enrollment, splenectomy status, presence of alloantibodies and 
years of transfusion exposure. Years of transfusion was included in the model because 
previous literature has shown an association between transfusion burden and formation of 
autoantibodies. In our model, only the presence of an alloantibody remained a significant 
independent predictor of autoimmunization.
Current Blood Processing and Transfusion Practices
For patients transfused in the year prior to study entry (n=330), 31% received blood matched 
for ABO/D only; 38% were also matched for C, E, and Kell; and 10% received extended 
phenotypically matched red cells. The extent of matching for 21% was unknown or variable. 
Additional processing included leukoreduction in 94%, washed packed red blood cells 
(PRBC) in 35% and irradiated cells in 33%.
Local blood banking practices varied. Two sites utilized standard ABO-Rh typing as their 
transfusion policy, with extended matching only once an antibody occurred. One site 
matched preventatively for C and E antigens, and three sites routinely matched for C, E, and 
Kell antigens. Extended red cell phenotypic matching, including Jkb antigen, was utilized at 
one site. All blood products were radiated at four sites regardless of individual patient risk. 
Three sites restricted radiation therapy to only thalassemia patients undergoing 
transplantation. One site utilized red cell washing as a standard technique of leukocyte 
depletion while others restricted washing to patients with a history of allergic reactions.
DISCUSSION
As the life span of thalassemia patients has dramatically increased, their cumulative 
exposure to red cell transfusions has resulted in this disease being the most heavily red-cell-
transfused syndrome worldwide. This report is an assessment of the morbidity of transfusion 
therapy in 407 thalassemia patients monitored by the CDC. It is the first report focusing only 
on the United States thalassemia population. In this report, half the study population is of 
Asian ethnicity and 27% immigrated to the United States. It includes information concerning 
transfusion complications not routinely studied in thalassemia such as serious allergic and 
hemolytic reactions. These complications and the variability in institutional approaches to 
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blood typing and processing may provide an impetus for developing national transfusion 
guidelines for thalassemia.
Hemosiderosis was the most common complication in this population.16 This cross-sectional 
report of patients at the time of enrollment at TTC’s across the United States was not 
designed to collect annual detailed information about iron intake, chelation, and iron loading 
to sensitive organs. However, despite new chelation therapies in this young population, 
hemosiderosis-induced organ dysfunction remains a serious problem.12,15,17–19 The 
prevalence of cardiac disease and endocrine dysfunction is lower than in cross-sectional data 
from previous decades, but its interpretation is limited by lack of laboratory confirmation, 
age at diagnosis, and detailed information regarding iron exposure, chelation compliance, 
treatment and screening practices.17 Serious thrombotic complications occurred particularly 
in patients who had undergone splenectomy and central line placement. Cappellini and 
others have recommended that these high-risk patients should receive preventative 
anticoagulation therapy.20
At enrollment, 24% of the transfused patients reported previous exposure to serious 
pathogens. While the actual source of infections cannot be unequivocally attributed to 
transfusion exposure given that some of the pathogens are endemic in areas outside of the 
US, this rate of exposure is likely an underestimate as exposure data was unknown in some 
cases and enrollment forms did not query about all possible pathogens. High rates of 
hepatitis and HIV are expected in this population, which includes adults transfused before 
adequate blood bank testing was in place.14,16,21–24 However, since 27% of the thalassemia 
patients have immigrated from areas that are still not providing uniform infectious screening 
of red cell transfusions, active infections are likely to occur in immigrant patients of all 
ages.25,26 The observations in our study of malaria and babesia are concerning. These 
organisms are among several that threaten the transfusion blood supply and blood banks do 
not routinely test for them.27–33 Recently, the CDC reported a marked increase in the 
number of imported malaria cases.32 Babesia is a growing transfusion risk in the United 
States and has been implicated in 10 of 28 deaths from blood products between 2005 and 
2008.27–29,34,35 Hemoglobinopathy patients are at particular risk for severe hemolysis that 
has been associated with babesia.15,36 The development of sensitive, specific assays for 
mass screening and a clear understanding of the risks of these infections is essential.
Almost half the transfused patients had experienced a transfusion reaction. Allergic 
reactions occurred in a third of patients, including at least two episodes of anaphylaxis. The 
frequency and severity of allergic reactions in chronically transfused thalassemia has not 
been well studied. It appears much higher than reported risk in the general population of 
approximately 1% for allergic reactions and 1:25,000 to 1:150,000 for anaphylaxis.23,37–41 
However, longitudinal studies are needed to confirm this. Although IgA deficiency is 
thought to be the most common cause of anaphylaxis, recently anti-haptoglobin antibody has 
been identified as a more common cause, particularly in people of Asian descent.42 These 
deficiencies have not been studied in the thalassemia population.
Alloimmunization is a serious adverse consequence of transfusion therapy. The overall 
proportion of alloimmunized patients in our study was 19%, with almost half the patients 
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having multiple antibodies and several hemolytic transfusion reactions. Understanding the 
predictors of alloimmunization would enable the implementation of a cost-effective 
extended matching program for at-risk patients. In our study, logistic regression analysis 
found that transfusion exposure was the strongest predictor of alloantibody formation.43 
While there are genetic and immunologic differences between patients that affect 
alloimmunization rate, it is likely that alloimmunization will continue to increase with age 
and transfusion burden in this thalassemia cohort.44–52 Transfusion exposure is the major 
factor in cumulative antibody risk.9,12 E, Kell, and C antigens accounted for the majority of 
hemolytic antibodies identified in this U.S. cohort of patients. Matching for these antigens 
has reduced alloimmunization and complications in other studies.6,9–12,53 Newer technology 
is making such preventative alloimmunization policies more cost-effective and supports 
their widespread implementation.51,53,54
Certain antibodies are unique to the Asian population and are likely to become an emerging 
transfusion-related complication in the United States.4,5,7 Our Chinese patient with an Anti-
Mia is one of the first North American thalassemia patients reported to have this antibody. In 
contrast, it accounts for over 30% of antibodies in thalassemia patients in China. The Mia+ 
antigen is almost uniquely found in Asian donors.4,5,7 In China, blood banks routinely 
screen donors for Mia+ red cells. As the Asian donor population increases in the United 
States, anti-Mia antibodies are likely to increase and donor screening may become 
necessary.
Our study supported the concept of immune tolerance developing in very young children 
under one year of age. The alloimmunization rate in children who began transfusion before 
one year of age was only 11%, in contrast to 27% who began transfusion after one year of 
age. Immune tolerance as a factor in the rate of red cell alloimmunization has previously 
been suggested.11,43,50 Recently, genetic factors influencing immune tolerance and 
alloimmunization have been identified.50
The effects of splenectomy on alloimmunization are unclear.9,12 Splenectomy markedly 
increases antigen and microparticle exposure in hemolytic anemias.55,56 This splenectomy-
induced antigen overload likely increases alloimmunization rate. Thompson, et al. found on 
multivariate analysis that duration of transfusion and splenectomy were risk factors for 
alloimmunization; however, they found splenectomy was not a significant risk factor in the 
older, chronically transfused patients.12 In our study, we observed splenectomy to be a risk 
factor on univariate analysis, but on multivariate analysis, only transfusion exposure was an 
independent predictor of alloimmunization. Differences between the two study populations 
and statistical modeling may account for the divergent findings. A large percentage of the 
Thalassemia Clinical Research Network included patients from international sites with 
differences in the percent of thalassemia diagnostic categories as well as age of onset and 
duration of transfusions.3,12 Clearly, both studies underscore transfusion exposure as a key 
predictor of alloimmunization.43
Autoantibodies are a serious problem, occurring in 6.5% of this population. This is much 
higher than in the general population.9,38,41,57 Their presence makes serologic cross-
matching difficult and often masks an undetected alloantibody, which if not recognized, can 
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result in a hemolytic transfusion reaction. Eighty-one percent of patients with an 
autoantibody had been alloimmunized. Multivariate analysis confirmed alloimmunization as 
the only significant independent predictor of autoimmunization. This data suggests that the 
control of alloimmunization may help to minimize autoantibody formation.
There is no national standardized procedure for preparation of red cells and no consensus 
among participating thalassemia centers. Transfusion policy for thalassemia is determined 
by generalized blood banking policies within each institution.58 The risk/benefit of extended 
red cell antigen matching for transfusions in hemoglobinopathies is debated.51,53,59,60 
Prospective studies indicate that antigen matching for Cc, Ee, D, and K reduces 
alloimmunization.6,51,53,61
Molecular red cell phenotyping of donors and recipients may increase the efficacy and 
efficiency of red cell matching and decrease blood inventory requirements.37,51,62 
Prospective outcome studies, including cost analysis, are needed.
The routine policy to radiate all blood products received by thalassemia patients at four of 
the participating centers is controversial.37,63 Radiation adds monetary cost and alters red 
cell metabolism, causing accelerated cellular potassium loss, elevated free plasma 
hemoglobin levels, and shortened red cell survival.37,64,65 The British Blood Transfusion 
Task Force and the Serious Hazards of Transfusion Program (SHOT), a United Kingdom 
hemovigilance effort, do not recommend radiated red cell units for hemoglobinopathies.64 
However, some centers with large populations of immunocompromised patients, cancer 
patients, and premature infants use universal radiation as a local policy. The overall best 
policy for use of radiated red cells in hemoglobinopathy patients needs to be addressed.
This study has several limitations. Data collected at enrollment was retrospective and not all 
of the information could be verified. While not the focus of this report, analysis of iron-
induced tissue injury is limited by a lack of actual tissue iron concentrations and specific 
vital organ functions as well as incomplete information regarding initiation and maintenance 
of chelation regimens. The intake forms did not quantitate the number of transfusion 
reactions per patient unit of exposure, which limits the determination of actual transfusion 
complication rates. Also, the laboratory testing for immune reactions was not centralized.
In summary, the thalassemia population in the United States is a multi-ethnic community 
including many recent immigrants who have a high rate of transfusion-related complications 
that exceeds that of other transfused populations.14,23,39,40,43 Transfusion reactions 
(including allo- and auto-immunization, hemolytic, and anaphylactic) are serious problems. 
Despite advances in iron chelation and blood safety, major improvements in hemosiderosis 
and transfusion-acquired infections are still needed. There is no standard practice among 
thalassemia centers on blood product preparation designed to limit transfusion reactions. 
This longitudinal surveillance project will enable the development of recommendations for 
interventions to prevent transfusion morbidity and evaluate long-term effectiveness. 
Ultimately, this will improve the safety of the national blood supply and its delivery.
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Appendix I: Site and Staff Information
Children's Hospital Los Angeles
4650 Sunset Blvd. MS 54
Los Angeles, CA 90027
Primary Investigator: Thomas Coates, MD
Site Coordinator: Tatiana Hernandez, CCRP
Children's Hospital and Research Center at Oakland
Pediatric Clinical Research Center
Outpatient Center, 1st Floor
747 52nd St
Oakland, CA 94609
Primary Investigator: Elliot Vichinsky, MD
Site Coordinator: Nancy Sweeters
Weill Medical College of Cornell University
525 East 68th St. Payson 695
New York, NY 10021
Primary Investigator: Patricia Giardina, MD
Site Coordinator: Dorothy Kleinert
Children's Hospital of Philadelphia
34th & Civic Center Boulevard
Philadelphia, PA 19104
Primary Investigator: Alan Cohen, MD
Site Coordinator: Sage Taylor Green
Ann & Robert H. Lurie Children’s Hospital of Chicago (formerly Children’s 
Memorial Hospital)
Division of Hematology/Oncology
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225 E. Chicago Avenue, Box #30
Chicago, IL 60611
Primary Investigator: Alexis Thompson, MD




Primary Investigator: Ellis Neufeld, MD, PhD
Site Coordinator: Jill Falcone
Children's Healthcare of Atlanta
5455 Meridian Mark Road
Suite 400
Atlanta, GA 30342
Primary Investigator: Jeanne Boudreaux, MD
Site Coordinator: Leann Schilling, MPH
Appendix 2 – Procedures for Laboratory Testing of Infections by the CDC
Patients who consented were surveyed clinically and 5ml of blood was collected by 
established phlebotomy methods. Specimens were prepared and mailed using the 
appropriate packaging to the CDC Serum Bank and Epidemic Response Laboratory in 
Lawrenceville, Georgia. Specimens received at the Serum Bank were assigned a specimen 
accessioning number and processed. Central testing for infectious disease was conducted at 
the CDC for the presence of hepatitis A, B, and C viruses, and HIV (appendix 2). After 
testing, the remainder of each serum specimen is used by the CDC to contribute to a serum 
bank for possible future use in evaluating the safety of blood products used by these 
patients.




aHBc IgM: Anti-HBC IgM (Ortho)
aHIV: Anit-HIV 1+2 (Ortho)
Performed on Abbot AxSYM (Abbott Diagnostics, Abbot Park, IL)
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aHCV: Abbott AxSYM Anti-HCV (Abbott Diagnostics)
aHAV: Abbott AxSYM HAVAB 2.0 (Abbott Diagnostics)
aHAV IgM: Abott AxSYM HAVAB-M 2.0 (Abbott Diagnostics)
Manual
RIBA: Chiron RIBA HCV 3.0 SIA (Ortho Clinical Diagnostics)
Performed on m1000 and Prism 7000 (Abbott Molecular)
HCV RNA: HCV RNA (Abbott Molecular)
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Table 1










Average Age (years)* 22.8 ± 13.1 21.9 ± 16.7 9.8 ± 10.2 21.3 ± 13.8
Diagnosis
β-thalassemia Major 82% (267/327) 31% (11/38) 14% (6/42) 70% (284/407)
β-thalassemia Intermedia 6% (20/327) 21% (8/38) 21% (9/42) 9% (37/407)
α-thalassemia Syndromes† 6% (20/327) 39% (15/38) 55%(23/42) 14% (56/407)
E-β-thalassemia 6% (20/327) 11% (4/38) 10% (4/42) 7% (28/407)
Gender
Female 53% (174/327) 76% (29/38) 48%(20/42) 55% (223/407)
Male 47% (153/327) 24% (9/38) 52%(22/42) 45% (184/407)
Race
Asian 48% (157/327) 68% (26/38) 57%(24/42) 51% (207/407)
White 49% (159/327) 24% (9/38) 17% (7/42) 43% (175/407)
Other 3% (11/327) 8% (3/38) 26%(11/42) 6% (25/407)
*
Median ages for ChronicTx (transfusion), IntermittentTx, and NeverTx, respectively: 31.3 (<1 – 58), 17.3 (1 – 61), and 7 (1–53)
†
HbH, HbHCS
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Table 2






























There were 10 antibodies without identified specificities. 47% of patients had multiple antibodies (see text for details).
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Table 3
Age of Initiation of Transfusion Therapy and Alloimmunization (n=297)
Age Transfusion Start
Rate of





On univariate analysis, infants initiating chronic transfusion therapy prior to one year of age had a lower rate of alloimmunization suggesting 
antigen tolerance as a mechanism.
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Table 4
Univariate Predictors of Alloimmunization in Chronically Transfused Patients (n=299)
Mean ± SD (n) P-value
Current Age P<.0001
With Alloantibody 29.5 ± 13.1 (64)
Without Alloantibody) 20.5 ± 12.3 (235)
Years of Transfusion P<.0001
With Alloantibody 25.9 ± 13.0 (64)












In a stepwise multivariate logistic regression of alloantibody formation in chronically transfused patients -- which included age at study 
enrollment (left as a continuous variable), years of transfusion, race (Asian vs. White), and splenectomy status -- only years of transfusion remained 
a significant independent predictor of alloimmunization.
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